Corium International (CORI) Earns Daily Coverage Optimism Score of 0.13

Media headlines about Corium International (NASDAQ:CORI) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corium International earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.073916546526 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Corium International (CORI) opened at $11.95 on Friday. Corium International has a 1 year low of $2.67 and a 1 year high of $12.32. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 2.41. The company has a market cap of $403.44, a PE ratio of -7.16 and a beta of 1.26.

CORI has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Corium International from a “hold” rating to a “sell” rating in a research report on Friday, December 29th. Needham & Company LLC upped their target price on shares of Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, November 20th. ValuEngine upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Jefferies Group set a $10.00 target price on shares of Corium International and gave the stock a “buy” rating in a research report on Sunday, October 29th. Finally, HC Wainwright set a $14.00 target price on shares of Corium International and gave the stock a “buy” rating in a research report on Wednesday, December 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $12.86.

In other news, major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $11.05, for a total value of $1,657,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 46.50% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Corium International (CORI) Earns Daily Coverage Optimism Score of 0.13” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.com-unik.info/2018/01/13/corium-international-cori-earns-daily-coverage-optimism-score-of-0-13.html.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit